Johnson & Johnson (NYSE:JNJ) Shares Purchased by Asset Planning Services Inc. LA ADV

Asset Planning Services Inc. LA ADV grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 37,224 shares of the company’s stock after acquiring an additional 1,120 shares during the period. Johnson & Johnson accounts for 2.6% of Asset Planning Services Inc. LA ADV’s portfolio, making the stock its 20th biggest position. Asset Planning Services Inc. LA ADV’s holdings in Johnson & Johnson were worth $5,383,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in JNJ. True North Advisors LLC increased its holdings in Johnson & Johnson by 2.9% in the fourth quarter. True North Advisors LLC now owns 9,046 shares of the company’s stock valued at $1,308,000 after buying an additional 253 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Johnson & Johnson by 10.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 1,292,787 shares of the company’s stock valued at $186,963,000 after acquiring an additional 120,815 shares during the last quarter. Sharp Financial Services LLC raised its position in shares of Johnson & Johnson by 14.9% during the 4th quarter. Sharp Financial Services LLC now owns 3,257 shares of the company’s stock valued at $471,000 after acquiring an additional 422 shares in the last quarter. Kelleher Financial Advisors boosted its holdings in Johnson & Johnson by 2.6% in the fourth quarter. Kelleher Financial Advisors now owns 6,516 shares of the company’s stock worth $942,000 after purchasing an additional 165 shares during the period. Finally, Westside Investment Management Inc. increased its stake in Johnson & Johnson by 13.3% during the fourth quarter. Westside Investment Management Inc. now owns 4,859 shares of the company’s stock valued at $703,000 after purchasing an additional 570 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

Shares of JNJ stock opened at $146.76 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The business’s fifty day moving average is $147.85 and its 200-day moving average is $155.99. The stock has a market cap of $353.34 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period in the previous year, the business earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. Stifel Nicolaus lowered their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday. Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Finally, Barclays lowered their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.